M. D. Chaplin

1.3k total citations
36 papers, 1.1k citations indexed

About

M. D. Chaplin is a scholar working on Pharmacology, Molecular Biology and Pharmacology. According to data from OpenAlex, M. D. Chaplin has authored 36 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pharmacology, 10 papers in Molecular Biology and 9 papers in Pharmacology. Recurrent topics in M. D. Chaplin's work include Inflammatory mediators and NSAID effects (9 papers), Pharmacogenetics and Drug Metabolism (8 papers) and Analytical Chemistry and Chromatography (3 papers). M. D. Chaplin is often cited by papers focused on Inflammatory mediators and NSAID effects (9 papers), Pharmacogenetics and Drug Metabolism (8 papers) and Analytical Chemistry and Chromatography (3 papers). M. D. Chaplin collaborates with scholars based in United States, Poland and Canada. M. D. Chaplin's co-authors include Eugene J. Segre, Richard Runkel, Enrico Forchielli, Gilbert J. Mannering, Hilli Sevelius, Gerhard Boost, C. Nerenberg, Rebecca L. Chan, Nancy Chu and William C. Cooper and has published in prestigious journals such as Clinical Infectious Diseases, Analytical Biochemistry and Biochemical and Biophysical Research Communications.

In The Last Decade

M. D. Chaplin

35 papers receiving 918 citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
M. D. Chaplin 361 311 186 155 151 36 1.1k
Dominick J. Tocco 292 0.8× 261 0.8× 408 2.2× 125 0.8× 292 1.9× 34 1.5k
G. Heinzel 391 1.1× 211 0.7× 156 0.8× 83 0.5× 136 0.9× 31 913
Peter H. Hinderling 186 0.5× 200 0.6× 252 1.4× 106 0.7× 189 1.3× 48 1.1k
James E. Patrick 184 0.5× 325 1.0× 277 1.5× 87 0.6× 228 1.5× 50 1.4k
Michael A. Wynalda 605 1.7× 251 0.8× 507 2.7× 250 1.6× 173 1.1× 33 1.7k
A. Sioufi 273 0.8× 170 0.5× 209 1.1× 87 0.6× 196 1.3× 73 1.5k
Fakhreddin Jamali 574 1.6× 318 1.0× 240 1.3× 98 0.6× 188 1.2× 39 1.4k
Lawrence S. Olanoff 141 0.4× 134 0.4× 123 0.7× 73 0.5× 91 0.6× 27 823
J Chakraborty 130 0.4× 169 0.5× 186 1.0× 74 0.5× 88 0.6× 57 1.0k
George W. Mihaly 217 0.6× 407 1.3× 149 0.8× 51 0.3× 456 3.0× 63 1.4k

Countries citing papers authored by M. D. Chaplin

Since Specialization
Citations

This map shows the geographic impact of M. D. Chaplin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. D. Chaplin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. D. Chaplin more than expected).

Fields of papers citing papers by M. D. Chaplin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. D. Chaplin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. D. Chaplin. The network helps show where M. D. Chaplin may publish in the future.

Co-authorship network of co-authors of M. D. Chaplin

This figure shows the co-authorship network connecting the top 25 collaborators of M. D. Chaplin. A scholar is included among the top collaborators of M. D. Chaplin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. D. Chaplin. M. D. Chaplin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mroszczak, Edward J., Daniel L. Combs, M. D. Chaplin, et al.. (1996). Chiral Kinetics and Dynamics of Ketorolac. The Journal of Clinical Pharmacology. 36(6). 521–539. 44 indexed citations
2.
Chaplin, M. D.. (1992). Bioavailability of nafarelin in healthy volunteers. American Journal of Obstetrics and Gynecology. 166(2). 762–765. 14 indexed citations
3.
Sommadossi, Jean‐Pierre, et al.. (1988). Clinical Pharmacokinetics of Ganciclovir in Patients with Normal and Impaired Renal Function. Clinical Infectious Diseases. 10(Supplement_3). S507–S514. 87 indexed citations
4.
Chan, Rebecca L., et al.. (1988). Absorption and metabolism of nafarelin, a potent agonist of gonadotropin-releasing hormone. Clinical Pharmacology & Therapeutics. 44(3). 275–282. 33 indexed citations
5.
Smith, Stephanie A., et al.. (1987). Inhibition and induction of hepatic drug metabolism in rats and mice by nafimidone and its major metabolite nafimidone alcohol.. Drug Metabolism and Disposition. 15(4). 571–578. 7 indexed citations
6.
Smith, Stephanie A., et al.. (1987). Disposition of nafimidone in rats.. Drug Metabolism and Disposition. 15(4). 565–570. 6 indexed citations
7.
Chan, Rebecca L. & M. D. Chaplin. (1985). Identification of major urinary metabolites of nafarelin acetate, a potent agonist of luteinizing hormone-releasing hormone, in the rhesus monkey.. Drug Metabolism and Disposition. 13(5). 566–571. 6 indexed citations
8.
Chu, Nancy, et al.. (1985). Disposition of nafarelin acetate, a potent agonist of luteinizing hormone-releasing hormone, in rats and rhesus monkeys.. Drug Metabolism and Disposition. 13(5). 560–565. 16 indexed citations
9.
McLean, James A., William W. Busse, R.K. Bush, et al.. (1985). A Comparison of Intranasal and Oral Flunisolide in the Therapy of Allergic Rhinitis. Allergy. 40(5). 363–367. 27 indexed citations
10.
Tomlinson, R. V., et al.. (1982). In vitro studies on the binding of cloprednol to human plasma proteins. Journal of Steroid Biochemistry. 16(1). 75–80. 7 indexed citations
11.
Teitelbaum, Philip, et al.. (1981). Mechanism for the oxidative defluorination of flunisolide.. Journal of Pharmacology and Experimental Therapeutics. 218(1). 16–22. 12 indexed citations
12.
Tökès, L, et al.. (1981). Isolation and identification of an oxidatively defluorinated metabolite of flunisolide in man.. Drug Metabolism and Disposition. 9(5). 485–486.
13.
Chaplin, M. D., William C. Cooper, Eugene J. Segre, et al.. (1980). Correlation of flunisolide plasma levels to eosinopenic response in humans. Journal of Allergy and Clinical Immunology. 65(6). 445–453. 31 indexed citations
14.
Sládek, Norman E., M. D. Chaplin, & Gilbert J. Mannering. (1974). Sex-dependent differences in drug metabolism in the rat. IV. Effect of morphine administration.. PubMed. 2(3). 293–300. 34 indexed citations
15.
Runkel, Richard, Enrico Forchielli, Hilli Sevelius, M. D. Chaplin, & Eugene J. Segre. (1974). Nonlinear plasma level response to high doses of naproxen. Clinical Pharmacology & Therapeutics. 15(3). 261–266. 107 indexed citations
16.
Chaplin, M. D., Adolph P. Roszkowski, & R. K. Richards. (1973). Displacement of Thiopental from Plasma Proteins by Nonsteroidal Anti-inflammatory Agents. Experimental Biology and Medicine. 143(3). 667–671. 19 indexed citations
17.
Runkel, Richard, Enrico Forchielli, Gerhard Boost, et al.. (1973). Naproxen-Metabolism, Excretion and Comparative Pharmacokinetics. Scandinavian Journal of Rheumatology. 2(sup2). 29–36. 42 indexed citations
18.
Chaplin, M. D. & Gilbert J. Mannering. (1970). Role of Phospholipids in the Hepatic Microsomal Drug-Metabolizing System. Molecular Pharmacology. 6(6). 631–640. 72 indexed citations
19.
Shoeman, Don W., M. D. Chaplin, & Gilbert J. Mannering. (1969). Induction of Drug Metabolism. Molecular Pharmacology. 5(4). 412–419. 6 indexed citations
20.
Chaplin, M. D. & Dwight J. Mulford. (1966). Amino Alcohols and Methyl Donors in Rats Fed Low Choline Diets Containing Added Cholesterol. Journal of Nutrition. 89(4). 501–504. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Dominick J. Tocco Breakdown of academic impact, for papers by G. Heinzel Breakdown of academic impact, for papers by Peter H. Hinderling Breakdown of academic impact, for papers by James E. Patrick Breakdown of academic impact, for papers by Michael A. Wynalda Breakdown of academic impact, for papers by A. Sioufi Breakdown of academic impact, for papers by Fakhreddin Jamali Breakdown of academic impact, for papers by Lawrence S. Olanoff Breakdown of academic impact, for papers by J Chakraborty Breakdown of academic impact, for papers by George W. Mihaly
Rankless by CCL
2026